The genetically heterogeneous Spinocerebellar ataxias (SCAs) are caused by Purkinje neuron dysfunction and degeneration, but their underlying pathological mechanisms remain elusive. The Src family of non-receptor tyrosine kinases (SFK) are essential for nervous system homeostasis and are increasingly implicated in degenerative disease. Here we reveal that the SFK suppressor Missing-in-Metastasis (MTSS1) is a novel ataxia locus that links multiple SCAs. MTSS1 loss results in increased SFK activity, reduced Purkinje neuron arborization, and low basal firing rates, followed by cell death. Surprisingly, mouse models for SCA1, SCA2, and SCA5 show elevated SFK activity, with SCA1 and SCA2 displaying dramatically reduced MTSS1 protein levels through reduced gene expression and protein translation, respectively.
Introduction
Neurons are non-dividing cells that depend on homeostatic regulation of protein, RNA, and metabolite turnover to permit dynamic synaptic connections that allow adaptation to changing environments. Loss of such mechanisms result in one of several hundred neurodegenerative disorders. Over 40 loci form the genetic basis for human Spinocerebellar Ataxia (SCA), a progressive motor disorder characterized by cerebellar atrophy and pervasive Purkinje neuron degeneration where patients experience poor coordination and balance, hand-eye coordination, dysarthria, and abnormal saccades.
One common phenotype prominent in multiple SCA animal models is the altered Purkinje neuron firing rates that precede motor impairment and cell death (1) (2) (3) , with restoration of the normal firing rates reducing Purkinje neuron death and improving motor function (4, 5) . Defects in many cell functions lead to SCA including effectors of transcription (6) , translation (7) , proteostasis (8, 9) , calcium flux (10, 11) , and cytoskeletal/membrane interactions (12, 13) . An open question remains how the many SCA genes interact to control firing rates and cell survival, with a common target emerging as a ideal treatment for the genetically diverse etiologies.
One such therapeutic target is the class of Src family of non-receptor tyrosine kinases (SFKs). Several SFKs are expressed in the nervous system and have partially overlapping functions. While single mutants for Src or Yes kinase have no overt neuronal phenotype (14, 15) , Fyn loss of function leads to increased Src activity and hippocampal learning and memory deficits (16, 17) Moreover, Fyn;Src double mutants rarely survive past birth and have severely disorganized cortical and cerebellar layers (15, 18) . SFKs are post-translationally regulated through activating and inhibitory phosphorylation marks deposited by inhibitory kinases and removed by receptor tyrosine phosphatases in a context dependent manner (19, 20) . SFK activation occurs rapidly in response to extracellular signals and in response to a variety of cellular stresses ranging from osmotic pressure (21) to tetanic stimulation (22) . Additionally, SFKs are inappropriately active in disease states including Amyotrophic lateral sclerosis (23), Alzheimer disease (24), and Duchenne muscular dystrophy (25).
Missing-in-Metastasis (MTSS1) is one of the defining members of the I-BAR family of negative membrane curvature sensing proteins first identified as being deleted in metastatic bladder cancer (26) . Although MTSS1 biochemically interacts with membranes and regulates the actin cytoskeleton (27), genetic studies reveal that MTSS1 functions in an evolutionarily conserved signaling cassette to antagonize Src kinase activity (28, 29) . Disruption of the MTSS1/Src regulatory cassette results in endocytosis and polarization abnormalities demonstrated by defects in primary cilia dependent hedgehog signaling, and hair follicle epithelial migration(28). In tissues requiring MTSS1 function, levels of active MTSS1 are critical, as loss (26) or gain (30) of MTSS1 has been associated with metastasis and invasion. Regardless of the particular phenotype, an evolutionarily conserved property of MTSS1 mutants is that loss of MTSS1 function can be reversed through the removal or inhibition of Src kinases. This property was first demonstrated through double mutant analysis in the fly ovary, and subsequently in mammalian tissue culture using Src kinase inhibitors (28, 29) . The availability of FDA-approved Src kinase inhibitors has led to the investigation of clinically relevant MTSS1 phenotypes with the hope of using SFK inhibitors to ameliorate them.
Although SFKs have been shown to regulate multiple classes of neurotransmitter receptors (31) they also function to control basic cytoskeletal components. Src regulates local actin polymerization (32) and endocytic receptor internalization (32-35).
The actin cytoskeleton plays a critical role in cell signaling, proliferation, motility, and survival. Local, rather than global, actin dynamics control homeostatic synaptic signaling, and abnormalities in actin regulation underlie a diversity of psychiatric and neuronal diseases including Amyotrophic lateral sclerosis (36), Schizophrenia, Autism Spectrum Disorders (37), and motor dysfunction such as spinocerebellar ataxia (SCA) (38). A major challenge remains to understand how actin cytoskeletal regulation controls synaptic function and to develop improved therapeutics for these common and poorly-treated diseases.
Here we reveal that actin regulator and SFK antagonist Mtss1 is a novel ataxia locus regulated by multiple SCA alleles that subsequently result in SFK hyper-activation.
We show that clinically-available Src inhibitors correct Purkinje neuron firing rates and delay ataxia progression, demonstrating a novel and druggable role for the evolutionarily conserved MTSS1/SFK network in Purkinje neuron survival and ataxia progression.
Results

Mtss1 null mice display a progressive ataxia
Mtss1 functions in a many tissues, and previous mutant alleles disrupting 5' exons resulted in mild lymphmagenesis (39), progressive kidney disease (40), and mild neurological phenotypes (41). Since Mtss1 has several possible internal promoters likely not affected by these mutant alleles (42) we generated a conditional mutant allele targeting the endophilin/Src interacting domain located in the final exon (MIM Ex15 , Fig   1A) (28, 29). Germline deletion with HPRT-cre resulted in the loss of MTSS1 protein as detected by an antibody specific to the N-terminal IMD domain (30) (Fig 1B) . The absence of detectable MTSS1 protein supports the idea that the MIM EX15 is a true null allele of Mtss1.
To our surprise, homozygous MIM EX15 mutants lack cilia phenotypes and display a striking and progressive cerebellar ataxia. To better understand the nature of MIM EX15 ataxia, we characterized MIM EX15 mutants using an open field test to evaluate gross motor control. MIM EX15 mutants had reduced velocity ( Fig 1C) and rearing behavior ( Fig   1D) , consistent with overall movement defects. To uncouple possible motor and behavioral abnormalities we evaluated MIM EX15 mutants with rotarod assay and observed coordination abnormalities in as early as 4 weeks of age (Fig 1E) . Many spinocerebellar ataxias display progressive neurologic phenotypes. To determine whether MIM EX15 animals showed progressive deterioration we employed a composite test measuring gait, grip strength and balance (43). We found MIM EX15 animals performed consistently worse than controls, with severity increasing with age ( Fig 1F) .
MIM EX15 heterozygous animals displayed no overt phenotype.
Reduced Mtss1 levels are associated with a variety of cellular phenotypes including reduced presentation of receptors on the cell membrane (44), and altered Purkinje neuron morphology (41). To determine the basis of the motor abnormalities and to distinguish among these possibilities we performed histological analysis. At 4 weeks, MIM EX15 mice are ataxic, yet their cerebella appeared grossly normal with intact granule, Purkinje neuron, and molecular layers. However, MIM EX15 mutants displayed a profound and progressive loss of Purkinje neurons starting at 8 weeks of age. Whereas wild type cerebella contain approximately 8 Purkinje neurons in a 250 µm linear distance, 8-week old mice retained only 25% of wild type, and 24 week MIM EX15 mutants contained only 5% of the total number of Purkinje neurons (Fig 1G) .
While ataxia genes can act in many cell types to regulate Purkinje cell function, MTSS1 is highly expressed in Purkinje cells, suggesting it is required in these cells for normal Purkinje cell function and survival. To confirm the Purkinje neuron defects seen in MIM EX15 animals are due to a cell autonomous requirement for Mtss1, we conditionally inactivated Mtss1 using the Purkinje neuron specific L7-Cre (MIM cko ) then compared Purkinje neuron morphology and loss to the global MIM EX15 mutant. MIM cko Purkinje neurons were mosaic for MTSS1 expression due to inefficient LoxP recombination. At 20 weeks MIM cko had reduced numbers of Purkinje neurons. In remaining Purkinje neurons, those lacking MTSS1 protein displayed thickened dendritic branches and reduced arbor volume, while neighboring Purkinje neurons with MTSS1 protein appeared normal ( Fig   1H) . We conclude that Mtss1 acts cell autonomously in Purkinje neurons to maintain dendritic structure, with loss of MTSS1 resulting in abnormalities and eventual cell death.
Mtss1 mutants have autophagocytic neurodegenerative disease
An emergent mechanism of cell loss during neurodegeneration is aberrant macroautophagy. Autophagy is essential for Purkinje neuron survival, as loss of autophagy (45, 46) results in cell death. Increased levels of early autophagy markers have been described in multiple neurodegenerative diseases including Huntington's disease (47), Alzheimer disease (48) , and SCA3 (49) . MIM EX15 mutants fit this pattern of disease as we observed multiple signs of autophagy. As early as 4 weeks, we observed increased Complex V/ATP synthase staining indicative of fused mitochondria as well as dramatically reduced staining for the Golgi body marker Giantin (Figs 2A, S1 ). By 8 weeks of age we could detect marked increased early autophagic marker LC3 and ubiquitinated proteins by immunofluorescence (Figs 2B, S1 ). We confirmed our immunofluorescence using electron microscopy of 8-week mutant cerebella. We observed Purkinje neurons with notched nuclei (Fig 2C) , a phenotype associated with autophagy, rather than the shrunken, condensed nuclei associated with apoptosis. We also observed frequent cases of autophagic vacuoles and swollen mitochondria (Fig 2D) , as well as late stage autophagic vacuoles filled with electron dense material (Fig 2E) .
Consistent with an autophagocytic cell death mechanism, we failed to see increased DNA breaks in MIM EX15 Purkinje neurons with TUNEL stain (Fig 2F) . In addition to autophagocytic neurodegeneration, MIM EX15 animals displayed increased GFAP positive glial infiltration (Fig 2G) consistent with reactive astroglyosis.
Mtss1 prevents SFK dependent Purkinje neuron firing defects and ataxia
To characterize cellular changes associated with the ataxia present in 4-week old MIM EX15 mice, we examined the dendritic tree of individual biocytin injected Purkinje neurons (Fig 3A) . Purkinje neuron dendritic arbor collapse has been observed in several SCA models including SCA1 (2), SCA5 (3), while many other models have shown thinned molecular layer including SCA2(1), SCA3 (50) , that likely reflects reduced Purkinje dendritic volume. Similarly, MIM EX15 mutants showed a 60% reduction in the expansiveness of the dendritic tree ( Fig 3B) and a significant decrease in the number of dendritic spines (Fig 3C) , although no significant difference was detected in spine length ( Fig 3D) or width (Fig 3E) .
In dermal fibroblasts and Drosophila border cells MTSS1 functions to locally prevent ectopic Src kinase activity and Mtss1 mutant phenotypes can be rescued by genetically removing Src kinase (28, 29). To determine if Mtss1 acts similarly in Purkinje neurons we evaluated SFK activity levels in cerebellar lysates from MIM EX15 mutants and found elevated levels of SFK Y416 (Fig 3F) indicative of increased SKF activity. Previous work has shown strong functional interactions between SKF and metabotropic glutamate receptor type I (mGluR1) neurotransmission at parallel fiber synapse (51) . To investigate whether MTSS1/SFK modulation of mGluR1 signaling forms the basis of the ataxia, we performed electrophysiological analysis of Purkinje neurons in cerebellar slices from MIM EX15 mice. We evaluated Purkinje neuron response to parallel fiber stimulation using calcium imaging. We found MIM EX15 mutant Purkinje neurons responded with a comparable increase of calcium dependent fluorescence to controls, while adding the mGluR1 antagonist CPCCOet abolished these responses (Fig 3G) . These data support MTSS1 acting post-synaptically to control Purkinje cell function.
Purkinje neurons maintain a cell autonomous tonic firing rate that is essential for their function (52, 53) . Since MIM EX15 Purkinje neurons responded normally to parallel fiber stimulation suggesting normal synaptic transmission, we assayed basal firing rate.
Purkinje neuron tonic firing rate is highly sensitive to temperature and may vary slightly between investigators (54). In our assays, wild type cells had a mean firing rate of 43±2Hz (n=2 animals, 62 cells), while MIM EX15 mutants exhibited a 12±1Hz mean rate (n=2 animals, 55 cells) (Figs 3H, 3I) . Previous studies of SCA mouse models demonstrated reduced tonic firing is a basis for ataxia (1, 3, 5) . Since basal firing is reduced at an age when MIM EX15 mice possess a normal number of Purkinje neurons, our results suggest neuron malfunction rather than loss underlies the initial ataxia phenotype.
MTSS1/Src double mutants rescue MTSS1 phenotypes in Drosophila and
vertebrate cell culture. To test the hypothesis that reducing SFK activity would ameliorate the MIM EX15 ataxia phenotype, we added the FDA-approved SFK inhibitor dasatinib to cerebellar slice preparations and measured basal firing rate, using a concentration approximately 2-fold over in vivo IC50 (200nM, Fig 3H, 3I) . Dasatinib significantly increased the MIM EX15 basal firing rate from baseline to 29±1Hz (n=2 animals, 62 cells). We also observed that dasatinib slightly reduced the wild type basal firing rate to 35±1Hz (n=2 animals, 79 cells). Time course experiments showed the increase in basal firing rate occurred over 5 hours (Fig S2) , consistent with a low concentration, high affinity mechanism of action. Direct modulation of ion channel or mGluR1 activity raises basal firing within minutes (4, 55) , suggesting that dasatinib works through a distinct mechanism. To determine whether SFK inhibition ameliorates ataxia in vivo we administered dasatinib directly to the cerebellum via minipumps to overcome poor CNS bioavailability (56) . Over 4 weeks, dasatinib treated MIM EX15 mice were protected from disease progression while untreated mice showed progressively worsening rotarod performance (Fig 3J) . These results demonstrate that Src family kinases act downstream of MTSS1 and that SFK inhibitors rescue Mtss1-dependent basal firing rate defects to slow disease progression.
Mtss1 is a translation target of ATXN2
The slow basal firing and ataxia preceding cell death seen in the MIM EX15 mutants resembles that seen in other SCA models such as SCA1, SCA2, and SCA5, prompting us to investigate whether MTSS1/SFK dysregulation occurs in other ataxias.SCA2 is caused by an expansion in the polyglutamine (polyQ) tract of the RNA binding protein ATAXIN-2 (ATXN2) (57) . The exact molecular defects that drive SCA2 pathogenesis remain unclear, as loss of function mice do not recapitulate the SCA2 phenotype (58) , while intermediate expansion alleles are associated with increased risk for frontotemporal dementia (59) . Atxn2 has an ancestral role in translation control (7, 60) , which may be altered with the SCA2 mutation, but the exact targets have yet to be described.
MTSS1 protein abundance is heavily regulated by metastasis-associated miRs
which bind to the MTSS1 3' untranslated region and reduce steady-state MTSS1 protein levels (61) (62) (63) (64) (65) To determine whether MTSS1 protein accumulation is sensitive to Atxn2 we examined the ATXN2 Q127 mouse model of SCA2 (1) . We found reduced Mtss1 abundance (Fig 4A, S3 ) and increased cerebellar SFK activity in ATXN2 Q127 animals compared to wild type littermates (Fig 4B) .
We sought to determine whether the age-dependent reduction in Purkinje neuron basal firing frequency seen in ATXN2 Q127 mice is due to elevated SFK activity.
Remarkably, addition of the Src inhibitor to ATXN2 Q127 cerebellar slices restored the basal firing rate from an average of 14±1Hz (n=2 animals, 100 cells) to nearly normal levels of 32±2Hz (n=2 animals, 72 cells; Fig 4C) . As in the MIM EX15 mutants, the firing rate reached maximal effect at 5-6 hours of Src inhibition (Fig S2) , leading us to conclude that inappropriate SFK activity underlies both the ATXN2 and MTSS1mediated firing phenotype.
The convergence of Mtss1 and ATXN2 on Src activity suggested they work in a common or parallel molecular pathway. To distinguish between these possibilities, we further interrogated MTSS1 protein levels in ATXN2 Q127 cerebella. We found a progressive reduction of MTSS1 protein in ATXN2 Q127 Purkinje neurons (Fig 4D) , leading to a 90% reduction at 24 weeks of age (Fig 4B, upper band) . We failed to see comparable changes in ATXN2 levels in MIMEX15 mice (Fig 4D) . Because ATXN2 possesses RNA binding activity, and Mtss1 contains a long 3'UTR, we hypothesized that ATXN2 controls Mtss1 translation in Purkinje neurons. RNA-IP followed by QPCR showed both WT ATXN Q22 and ATXN2 Q108 specifically bound MTSS1 mRNA compared to GAPDH control. (Fig 4E) . Using a luciferase reported fused to the MTSS1 3' UTR we were able to map the ATXN2 interacting domain to a central 500bp region that was sufficient for both RNA-protein interaction and translation control (Fig S3) . Furthermore, polyribosome fractionation experiments revealed that pathogenic ATXN2 Q108 was sufficient to block the translation of reporter mRNA fused to the MTSS1 3'UTR shifting the transcript from the polyribosome fractions to a detergent resistant fraction consistent with stress granules (Fig 4F) . These results suggest the pathogenic ATXN2 acts directly as a dominant negative RNA binding protein preventing MTSS1 translation. Notably, we observed MTSS1 abundance is reduced in human SCA patient cerebellum, bolstering the evolutionary conservation of the ATXN2/MTSS1 interaction (Fig 4G) .
SFK inhibition rescues Purkinje neuron firing across SCA
Two other SCA mouse models have been shown to have slow basal firing rates, SCA1 (2) and SCA5 (3) . Much like SCA2, SCA1 is due to a polyQ expansion in the RNA binding protein ATAXIN-1 (ATXN1) (66) . One observed result of the SCA1 allele is changed ATXN1 association with transcriptional regulatory complexes (67), leading to vastly different Purkinje neuron mRNA profiles (68) . However, the exact targets that drive SCA1 pathogenesis are still being determined. Unlike SCA1 and SCA2, SCA5 a pure cerebellar ataxia due to lesions in the structural protein β-III spectrin (SPTNB2) (13) . SPTNB2 directly binds and controls the cell membrane localization of EAAT4 glutamate reuptake receptor which helps clear synaptic glutamate in several types of neurons (12, 69) .
If SCA1 or SCA5 acts similarly to SCA2 by regulating the MTSS1/SFK cassette, we would expect decreased MTSS1 abundance and increased active SFK Y416 . Indeed, in the ATXN1 Q82 mouse model of SCA1 (70) we observed a dramatic decrease in MTSS1 protein abundance and corresponding increase in SFK Y416 at 15 weeks (Fig 5A) .
Atxn1 pathogenicity is partially driven by phosphorylation at serine 776 (67) , which was unchanged in MIM EX15 mice, suggesting MTSS1 is a target of the SCA1 allele (Fig 5B) .
Additionally, Mtss1 transcript abundance is reduced at multiple ages in ATXN1 Q8 mice (68) (Fig 5C) . We found treating ATXN1 Q82 slices with dasatinib increased the basal firing rate from a baseline of 15±1Hz (n=3 animals, 21 cells) to 23±2Hz (n=3 animals, 21 cells), a level statistically indistinguishable from dasatinib-treated controls (Fig 5C) .
By contrast, the Sptbn2 knockout model of SCA5 (βIII -/-)(3),, showed no change in MTSS1 protein abundance yet demonstrated a clear increase in SFK Y416 phosphorylation (Fig 5D) . We fail to see changes in SPTNB2 abundance in MIM EX15 mice, and detect only a subtle decrease in SPTNB2 levels in 24-week ATXN2 Q127 mice consistent with reduced Purkinje neuron dendritic arbor size (Fig 5F, 5G) . These data suggest that SPTNB2 works through a different mechanism than MTSS1, ATXN1, or ATXN2, yet we still observed increased basal firing from 25±1Hz (n=2 animals, 31 cells) to 30±2Hz (n=3 animals, 43 cells) over a 7-hour period of dasatinib treatment (Fig 5H) .
Discussion
While SCA gene functions appear heterogeneous, our study establishes a genetic framework to understand how several SCA loci regulate SFK activity to ensure neuronal homeostasis and survival. We identify SPTNB2 and MTSS1, proteins that link the cell membrane and actin cytoskeleton, as negative regulators of Src family kinases.
We show that MTSS1 is a target of the SCA genes ATXN1 and ATXN2 (Fig 5 I) , and that increased SFK activity from lesions in MTSS1, SPTNB2 (SCA5), ATXN1, and ATXN2 reduces Purkinje neuron basal firing, an endophenotype that underlies multiple ataxias, providing support for the clinical use of SFK inhibitors in many SCA patients.
Our Disruption of post-transcriptional gene regulation leading to altered proteostasis has recently emerged as a key contributor to neurodegeneration. In the cerebellum, reducing the abundance of the RNA-binding protein Pumilio leads to SCA1-like neurodegeneration through a specific increase in ATXN1 protein levels (73, 74 ). Yet
Pumillio binds hundreds of transcripts to control protein levels (75, 76) , suggesting that changing protein abundance of a few key effector genes post-transcriptionally leads to disease. Our data demonstrate that MTSS1 is a key effector gene whose activity is tightly regulated to prevent Purkinje neuron malfunction. Post-transcriptional control of MTSS1 is disrupted in many disease states such as cancer, where MTSS1 levels are reduced by locus deletion or miRNA overexpression and are associated with increased metastasis and poorer prognosis (62, 77) . In Purkinje neurons, the SCA1 ATXN1 Q82 allele reduces MTSS1 transcript levels. ATXN1 is thought to act as a transcriptional regulator by associating with the transcriptional repressor Capicua (CIC) (67), though it remains to be shown whether the ATXN1/CIC complex occupies the MTSS1 promoter.
By contrast, the SCA2 allele ATXN2 Q58 binds the MTSS1 3' UTR to prevent ribosome binding and MTSS1 translation, ultimately leading to increased SFK activity. ATXN2
(and the redundant gene ATXN2L) have recently been identified in a large complex of 3'
UTR binding proteins that regulate networks of genes controlling epithelial differentiation and homeostasis (78) . Our results suggest other ataxia disease genes that control proteostasis may also regulate MTSS1 abundance, and the strong role for miRNAs controlling MTSS1 abundance in cancer suggest they may also function as effectors of as yet undescribed ataxia loci. were designed for oncology targets and lack potent central nervous system activity.
Further, while we provide data for kinase inhibition to suppress MTSS1 loss, we have previously shown that SFK regulation by regulatory receptor tyrosine phosphatases, or deletion of endocytic adapter proteins can also revert the effects of MTSS1 loss. Given the challenge of developing specific kinase inhibitors, our work opens additional therapeutic classes to alleviate the progression of neurodegenerative diseases.
In summary, the identification of Mtss1 as a novel recessive ataxia locus extends the physiologic functions requiring the MTSS1/SFK signaling cassette, which include cell polarity, migration, and cancer metastasis. Each of these disparate processes highlight the common role MTSS1 plays integrating the cell membrane and cytoskeletal response to local signals, as the dendritic spine defects seen in MIM EX15 -mutant Purkinje neurons (Fig 2A-E) recalls the loss of directional cell extensions in migrating Drosophila border cells (29). They also reinforce the critical need to suppress inappropriate SFK activity, and provide a therapeutic opportunity for otherwise devastating and debilitating diseases. ATXN2 Q127 : ATXN2 Q127 mice were previously characterized in (1).
Author Contributions
ATXN1 Q82 : ATXN1Q82 mice were previously characterized in (70) .
SPTNB2: SPTNB2 null mice were previously characterized in (3) .
METHOD DETAILS
Behavior testing:
Rotarod and activity chamber testing was performed by the Stanford Behavioral and Functional Neuroscience Lab. For rotarod mice were trained on 2-20rpm accelerating rod for 4 trials with 15 minute rest intervals between trials. Testing was performed after one rest day at 16rpm constant speed. For activity chamber mice were placed in chamber and measured for 10 minutes 3 times on separate days.
Composite Limb Gait Ledge test was performed as in (43).
Cerebellar dasatinib administration:
Mice were trained on 4-40rpm accelerating rotorod with 15 minute rest intervals. Mice were tested on the same 4-40rpm paradigm after a rest day.
Dasatinib was dissolved in 40% capitsol to a 9mM solution, then diluted in acsf and loaded into azlet pump 1004. Cannulas were inserted at midline, -6.2mm cadual -2.5 DV from bregma. Sutures were closed with ethilon and mice were allowed to recover before subsequent rotarod tests.
Western blot:
Isolated tissues were lysed in RIPA buffer supplemented with complete mini protease inhibitor (Roche) and PhosStop (Roche). Protein concentrations were normalized by using the BCA assay (Pierce). Proteins were electrophoresed on Novex 4-12% or 3-8% gradient gels. Rabbit anti-Src-Y416 (CST 2101S or CST 6943S), mouse anti-beta actin (Sigma), rabbit anti-Sptbn2 (Thermo PA1-46007), rabbit anti-Atxn2 (Sigma HPA021146), mouse anti-Atxn1 (abcam ab63376) primary antibodies were detected with LICOR secondary antibodies.
Antibodies and Immunofluorescence:
Isolated cerebella were immersion fixed in 4% paraformaldehyde and embedded in paraffin. 7µm sections were cut and deparaffinized using standard conditions before staining. Sections were blocked with 20% horse serum 0.3% Triton X-100 in PBS. The following antibodies were used at 1:1000 dilutions: Alexafluor conjugated secondary antibodies were purchased from Invitrogen. Images were acquired either on a Leica SP2 AOBS laser scanning microscope or a Zeiss axioplan widefield scope.
Luciferase assay:
Luciferase activity was measured using Electrophysiology:
Preparation of Cerebellar Slices (SCA2 and Mtss1)
Acute parasagittal slices of 285µm thickness were prepared from the cerebella of 4-to 8-
week-old mutant and control littermates following published methods (1) . In brief, brains were removed quickly and immersed in an ice-cold artificial cerebrospinal fluid (ACSF or extracellular) solution consisting of: 119 mM NaCl, 26 mM NaHCO 3 , 11 mM glucose, 2.5 mM KCl, 2.5 mM CaCl 2 , 1.3 mM MgCl 2 and 1 mM NaH 2 PO 4 , pH 7.4 when gassed with 5% CO 2 / 95% O 2 . Cerebella were dissected and sectioned using a vibratome (Leica VT-1000). Slices were initially incubated at 35 °C for 35 min, and then at room temperature before recording in the same ACSF. Dasatinib (200nM) was added during cerebellar sectioning and remained on the slices for recording.
Recordings (SCA2 and Mtss1)
Non-invasive extracellular recordings were obtained from Purkinje neurons in voltageclamp mode at 34.5 ± 1°C. The temperature was maintained using a dual channel heater controller (Model TC-344B, Warner Instruments) and slices were constantly perfused with carbogen-bubbled extracellular solution alone or with 200 nM dasatinib.
Cells were visualized with an upright Leica microscope using a water-immersion 40× objective. Glass pipettes were pulled with Model P-1000 (Sutter instruments). Pipettes Results are presented as mean ±SEM. All chemicals were purchased either from Sigma Aldrich, Tocris and Invitrogen, USA.)
Biocytin fills of Purkinje neurons or Intracellular labeling of Purkinje neurons with
Biocytin:
(Nikon) with infrared differential interference contrast (IR-DIC) optics that were visualized using NIS Elements image analysis software (Nikon). Borosilicate glass patch pipettes were pulled with resistances of 3-5 MΩ. Recordings were made 5 hours after slice preparation. Data were acquired using an Axon CV-7B headstage amplifier, Axon
Multiclamp 700B amplifier, Digidata 1440A interface, and pClamp-10 software (MDS Analytical Technologies). In all cases, acquired data were digitized at 100 kHz.
QUANTIFICATION AND STATISTICAL ANALYSIS
For cell counts, firing rates, rotorod and activity chamber 2-tailed non-homodidactic Student's T-test was used to calculate significance.
For cerebellar dasatinib cohorts of 2-5 mice were tested. Analysis was T-test with twostage step-up method of Benjamini, Krieger and Yekutieli with a 5% FDR for multiple test correction.
For electrophysiology 2-3 mice per condition were evaluated with investigator blinded to genotype. For MTSS1 rotorod and activity chamber cohorts of 10 age matched animals were examined with investigator blind to genotypes.
For western blots and immune fluorescence 2-3 mice per genotype and age were evaluated.
